Vivus (VVUS) - FREE Research Report

Astrue Michael J who is Director at Vivus bought 10,000 shares at $11.96 on Sept. 6, 2013. Following this transaction, the Director owned 10,000 shares meaning that the stake was reduced by 100% with the 10,000 share transaction.

The shares most recently traded at $10.87, down $1.09, or 10.02% since the insider transaction. Historical insider transactions for Vivus go as follows:

  • 24-Week # shares bought: 15,000

The average volume for Vivus has been 2.4 million shares per day over the past 30 days. Vivus has a market cap of $1.1 billion and is part of the health care sector and drugs industry. Shares are down 19.22% year to date as of the close of trading on Friday.

VIVUS, Inc., a biopharmaceutical company, engages in developing and commercializing therapies to address unmet needs in obesity, sleep apnea, diabetes, and sexual health. Currently there are 4 analysts that rate Vivus a buy, 3 analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on VVUS - FREE

TheStreet Quant Ratings rates Vivus as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity, weak operating cash flow and generally high debt management risk. Get the full Vivus Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

Middleby (MIDD) Stock Jumps on Q2 Earnings Beat

Today's Strong And Under The Radar Stock Is Middleby (MIDD)

3 Industrial Stocks Nudging The Industry Higher

12 Stocks That Benefit From Rising First-Time Home Buying

Trade-Ideas: Middleby (MIDD) Is Today's "Water-Logged And Getting Wetter" Stock